The trial will analyse the potential of BI 771716 in preserving vision in patients with geographic atrophy. Credit: Prostock-studio / Shutterstock.

Boehringer Ingelheim and CDR-Life are set to begin a Phase I clinical trial to analyse the potential of BI 771716 in preserving vision in patients with geographic atrophy (GA). 

The two-part, non-randomised, open-label trial will analyse the safety, pharmacokinetics and tolerability of different intravitreal doses of BI 771716.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

It will enrol patients aged 50 years and older, who will each be given a single rising dose or multiple doses of BI 771716.

The first part of the study will take place over three months and assess a single dose of BI 771716 injected directly into the GA-impacted eye of the patient.

The trial’s second segment will run for four months and involve subjects being given two doses of BI 771716 at a gap of four weeks.

BI 771716 is an antibody fragment-based therapy that was created using a technology licenced from CDR-Life.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Its smaller size allows it to penetrate layers of the retina to reach the site of the target associated with the GA disease pathology.

Boehringer Ingelheim Discovery Research global head and corporate senior vice-president Clive Wood said: “We are very pleased to start the clinical evaluation of BI 771716, which resulted from collaborative efforts with CDR-Life.

“This brings us another step closer to achieving our vision of developing precise treatments to stop vision loss, protecting and preserving both people’s eyesight and quality of life.” 

CDR-Life CEO Christian Leisner said: “We are delighted to see this compound progress into the clinic.

“We are looking forward to BI 771716 potentially becoming a treatment to transform the lives of people living with GA.”

In August this year, Boehringer Ingelheim announced the advancement of its potential weight loss drug, survodutide, into three international Phase III clinical trials in patients with obesity or who are overweight.

The company developed survodutide in partnership with Danish biopharmaceutical company Zealand Pharma.